Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302863 | PMC |
| http://dx.doi.org/10.1007/s11739-022-03056-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TM6SF2 -rs58542926 Genotype Has Opposing Effects on Incidence of Hepatic and Cardiac Events in a Community Cohort.
Am J Gastroenterol
October 2024
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Introduction: TM6SF2 -rs58542926-T is associated with increased cirrhosis and modestly decreased coronary artery disease prevalence. However, relative effects of TM6SF2 genotype on major adverse cardiovascular events (MACE) vs liver-related events (LRE) are not known.
Methods: We used the UK Biobank, a prospective cohort with genetic and inpatient diagnosis data.
Fighting Amyotrophic Lateral Sclerosis by Protecting the Liver? A Prospective Cohort Study.
Ann Neurol
October 2024
Department of Neurology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Article Synopsis
- * The study analyzed data from over 500,000 UK Biobank participants, discovering that those with liver disease were significantly more likely to develop ALS, with a hazard ratio of 7.35.
- * The findings indicated that higher levels of liver disease activity measured by cT1 (a specific MRI metric) correlated with increased ALS risk, even after adjusting for various health factors.
QTc Prolongation to Predict Mortality in Patients Admitted with COVID-19 Infection: An Observational Study.
Curr Vasc Pharmacol
June 2024
Division of Internal Medicine C, Department of Medicine, University of Verona, Italy.
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes Coronavirus disease 2019 (COVID-19), characterized by pulmonary infection ranging from asymptomatic forms to respiratory insufficiency and death. Evidence of cardiac involvement in COVID-19 is increasing, and systemic inflammation or direct heart damage by SARS-CoV-2 can prolong the corrected QT interval (QTc).
Methods: In this observational study, a total of 333 consecutive patients admitted to the Covid Center of Verona University Hospital from November 2020 to April 2021 were included.
MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease.
Aliment Pharmacol Ther
December 2023
Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.
Background: Early screening may prevent fibrosis progression in metabolic-associated fatty liver disease (MAFLD).
Aims: We developed and validated MAFLD fibrosis score (MFS) for identifying advanced fibrosis (≥F3) among MAFLD patients.
Methods: This cross-sectional, multicentre study consecutively recruited MAFLD patients receiving tertiary care (Malaysia as training cohort [n = 276] and Hong Kong and Wenzhou as validation cohort [n = 431]).
Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
Hepatol Res
October 2023
Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Article Synopsis
- The study investigates the recent prevalence of hepatitis delta virus (HDV) infections among patients with hepatitis B virus (HBV) in Japan, as it has not been updated for over two decades.
- Researchers screened 1,264 HBV patients at Hokkaido University Hospital, concluding that 1.7% had detectable anti-HDV antibodies.
- The findings indicate that those with anti-HDV antibodies had a higher prevalence of liver cirrhosis and experienced faster progression of liver fibrosis, emphasizing the need for routine HDV testing in similar patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!